Aurora-A amplification associated with BRCA2 mutation in breast tumours.
Potential interaction of Aurora-A amplification and BRCA2 mutation was examined in breast tumours from BRCA2 999del5 mutation carriers (n=20) and non-carriers (n=41). Aurora-A amplification studied by FISH was significantly more common in breast tumours from BRCA2 mutation carriers (p=0.0005). Extensive Aurora-A amplification was also detected on metaphase chromosomes in three breast epithelial cell lines with the same BRCA2 mutation. In addition, significant association was found between Aurora-A amplification and TP53 mutations in non-BRCA2 mutation carrier tumours (p=0.007). These results suggest that breast tumours with mutations in BRCA2 or TP53 could be promising candidates for Aurora-A targeted treatment.
Bodvarsdottir
Sigridur K
SK
Icelandic Cancer Society, Skogarhlid 8, 105 Reykjavik, Iceland; University of Iceland, Department of Medicine, Vatnsmyrarvegi 16, 101 Reykjavik, Iceland.
Hilmarsdottir
Holmfridur
H
Birgisdottir
Valgerdur
V
Steinarsdottir
Margret
M
Jonasson
Jon G
JG
Eyfjord
Jorunn E
JE
D064127:Aurora Kinases; D024682:BRCA2 Protein / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology*; D002460:Cell Line; D004252:DNA Mutational Analysis; D005260:Female; D005784:Gene Amplification; D006579:Heterozygote; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D009154:Mutation; D016017:Odds Ratio; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
D024682:BRCA2 Protein; D016159:Tumor Suppressor Protein p53; D064127:Aurora Kinases; D017346:Protein Serine-Threonine Kinases